EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay

Tadayoshi Hashimoto, Yoshiaki Nakamura, Eiji Oki, Shin Kobayashi, Junichiro Yuda, Taro Shibuki, Hideaki Bando, Takayuki Yoshino

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02493-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Tadayoshi Hashimoto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Neoplasm, Residual, Whole Genome Sequencing, Biomarkers, Tumor. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor DNA (ctDNA) is the fraction of cell-free DNA in patient blood that originates from a tumor. Advances in DNA sequencing technologies and our understanding of the molecular biology of tumors have increased interest in exploiting ctDNA to facilitate detection of molecular residual disease (MRD). Analysis of ctDNA as a promising MRD biomarker of solid malignancies has a central role in precision medicine initiatives exemplified by our CIRCULATE-Japan project involving patients with resectable colorectal cancer. Notably, the project underscores the prognostic significance of the ctDNA status at 4 weeks post-surgery and its correlation to adjuvant therapy efficacy at interim analysis. This substantiates the hypothesis that MRD is a critical prognostic indicator of relapse in patients with colorectal cancer. Despite remarkable advancements, challenges endure, primarily attributable to the exceedingly low ctDNA concentration in peripheral blood, particularly in scenarios involving low tumor shedding and the intrinsic error rates of current sequencing technologies. These complications necessitate more sensitive and sophisticated assays to verify the clinical utility of MRD across all solid tumors. Whole genome sequencing (WGS)-based tumor-informed MRD assays have recently demonstrated the ability to detect ctDNA in the parts-per-million range. This review delineates the current landscape of MRD assays, highlighting WGS-based approaches as the forefront technique in ctDNA analysis. Additionally, it introduces our upcoming endeavor, WGS-based pan-cancer MRD detection via ctDNA, in our forthcoming project, SCRUM-Japan MONSTAR-SCREEN-3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNANeoplasm, ResidualWhole Genome SequencingBiomarkers, TumorHumansJapanColorectal NeoplasmsPrognosisPrecision MedicineNeoplasms

Stichwörter der Autor:innen

CIRCULATE-JapanCirculating tumor DNAMONSTAR-SCREENMolecular residual diseaseSCRUM-JapanWhole genome sequencing

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. tyoshino@east.ncc.go.jp.

Zitieren

APA

Hashimoto, T., Nakamura, Y., Oki, E., Kobayashi, S., Yuda, J., Shibuki, T., Bando, H., & Yoshino, T. (2024). Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02493-4

Vancouver

Hashimoto T, Nakamura Y, Oki E, Kobayashi S, Yuda J, Shibuki T, et al. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02493-4

BibTeX
@article{Hashimoto2024,
  author = {Hashimoto, Tadayoshi and Nakamura, Yoshiaki and Oki, Eiji and Kobayashi, Shin and Yuda, Junichiro and Shibuki, Taro and Bando, Hideaki and Yoshino, Takayuki},
  title = {Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02493-4}
}
Kostenlos starten →